AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer
AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer
Reuters: Health
British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.
Reuters: Health
British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.
Comments
Post a Comment